OXFORD: Ingenta plc (AIM: ING), a provider of software and services to the publishing and media industries, announced Tuesday the acquisition of an initial stake in AI legal software firm FirstAida Limited and the appointment of its founder, Dr. Dan Brown, to the board.
The company acquired an initial 24.9% equity stake in FirstAida through a share transaction valued at approximately $0.5 million based on Ingenta’s share price prior to the announcement. Ingenta has secured a unilateral right to acquire the remaining 75.1% of FirstAida within 9 to 15 months, contingent on performance targets.
“This acquisition extends Ingenta’s capabilities into AI-led IP infringement investigation while creating significant cross-selling opportunities,” the company stated.
Dr. Dan Brown, founder of FirstAida and Entrepreneur in Residence at University College London’s Computer Science department, has been appointed as a Non-Executive Director effective immediately. Brown previously founded Meganexus Ltd, a SaaS provider acquired by NEC in January 2026.
Strategic Rationale and Technology
FirstAida has developed a suite of agentic AI-based legal software and services adjacent to Ingenta’s existing IP management suite. Ingenta’s current products allow rights distributors to manage contract creation, rights management, and royalty calculations, but do not currently provide a solution for investigating potential IP abuse.
The company noted that distributors of publishing rights, standards data, and copyright holders of music, video, and gaming content are increasingly suffering from illegal copying and the unauthorized training of third-party AI agents. FirstAida aims to provide AI-based support services to legal firms and rights holders in the professional, legal, and academic publishing markets.
Terms and Conditions
Consideration for the initial stake will be satisfied through the transfer of 587,930 existing ordinary shares from treasury and the issue of 210,131 new ordinary shares, comprising 798,061 ordinary shares in total.
The company has the right to acquire the remaining stake through the issue of up to 1,958,876 new ordinary shares, contingent on FirstAida achieving annualized recurring revenues of at least £375,000 per annum over the next 15 months. The company may waive this condition at its discretion.
Additional deferred consideration of up to 875,000 new ordinary shares may be payable should contracted revenues of FirstAida exceed £500,000 six months after exercise of the option. Based on Ingenta’s share price prior to the announcement, the maximum total consideration, including deferred consideration, would be approximately $2.3 million, equivalent to 1.5 times contracted revenues at that time.
Lock-in and Voting Rights
The Initial Consideration Shares, Remaining Consideration Shares, and Deferred Consideration Shares will be subject to lock-in arrangements.
Application has been made for the 210,131 new ordinary shares to be admitted to trading on AIM on Monday, Aug. 10, 2026. Following the transfer and admission, no ordinary shares will remain in treasury, and the total number of Ingenta ordinary shares in issue and total voting rights will be 15,308,256.
Company Outlook and Interim Results
FirstAida, based in the UK with a software team in Pune, India, currently has minimal revenues and is expected to generate recurring revenue from publishing and legal advisory customers in H2 2026. Dr. Brown has entered into financing arrangements to fund working capital requirements.
Ingenta expects to announce unaudited results for the six months ended June 30, 2026, on Sept. 23, 2026. Further updates on FirstAida will be provided at that time.
